A triple-blind, placebo-controlled, randomized clinical trial of CANnabinoids for Drug Resistant Epilepsy (CAN-DRE) in adults and children
Our clinical trial investigating CBD alone and in combination with THC in drug resistant epilepsy (CAN-DRE) has been funded by CIHR.
The protocol is currently in development. More information coming soon!
Image Description: Arm 1: CBD placebo + THC placebo, Arm 2: CBD + THC placebo, Arm 3: CBD + THC. Timeline of CAN-DRE study visits: Visit 1, Baseline (30 days), Visit 2, CBD escalation (40 days), Visit 3, THC escalation (56 days), Visit 4, Maintain & observe (30 days), Visit 5.
This study was funded by the Canadian Institute for Health Research (CIHR).